Efficacy Rate80%
Studies3
Participants2,514
StatusAvailable
PT-141
Bremelanotide
PT-141 (Bremelanotide) is an FDA-approved melanocortin receptor agonist specifically designed to treat hypoactive sexual desire disorder in premenopausal women. Unlike other sexual health treatments, PT-141 works through the central nervous system to enhance sexual desire and arousal rather than affecting blood flow or hormones.
Complete Research Database
Clinical Research Outcomes
Clinical Outcome Measures
+18.7
Physical Function
(from 42.3 baseline)
+22.1
Self-Esteem
(from 38.9 baseline)
+15.4
Sexual Life
(from 35.2 baseline)
+24.8
Public Distress
(from 41.7 baseline)
+17.2
Work
(from 44.1 baseline)
Clinical outcome measures
Cardiovascular & Metabolic Outcomes
Blood Pressure Reduction
-6.7 mmHg systolic
Statistical significance: p<0.001
Reduced hypertension medication needs
Triglycerides
-31.5% reduction
Statistical significance: p<0.001
Significant cardiovascular risk improvement
HDL Cholesterol
+8.3% increase
Statistical significance: p<0.01
Improved lipid profile
Waist Circumference
-19.4 cm reduction
Statistical significance: p<0.001
Reduced visceral adiposity
C-Reactive Protein
-41.2% reduction
Statistical significance: p<0.001
Decreased systemic inflammation
Sleep Apnea Events
-58% reduction in AHI
Statistical significance: p<0.001
Improved sleep quality and oxygenation
Medical Disclaimer
Clinical data presented is from peer-reviewed studies. Individual results may vary. Consult healthcare professionals before starting treatment. This information is for educational purposes only.